Bulletin
Investor Alert

Market Pulse Archives

July 8, 2020, 7:39 a.m. EDT

Merck, Eisai to put experimental cancer combination in new clinical trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Eisai Co. Ltd. (4523)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK +1.03% gained 0.1% in premarket trading on Wednesday after it received a complete response letter from the Food and Drug Administration for an application to approve Keytruda in combination with Eisai Co. Ltd.'s /zigman2/quotes/203064480/delayed JP:4523 -3.88% Lenvima for a new indication. The regulator said the data that was provided in the application for the investigational combination therapy as a first-line treatment for unresectable hepatocellular carcinoma didn't demonstrate "a meaningful advantage" over existing therapies. The companies plan to conduct a new Phase 3 trial, which is already fully enrolled. They are also testing the Keytruda/Lenvima combination in 17 other clinical trials. Merck's stock has declined 13.4% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.58% is down 2.6%.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 76.36
+0.78 +1.03%
Volume: 8.60M
June 24, 2021 4:02p
P/E Ratio
27.61
Dividend Yield
3.40%
Market Cap
$191.37 billion
Rev. per Employee
$648,824
loading...
/zigman2/quotes/203064480/delayed
JP : Japan: Tokyo
¥ 11,775.00
-475.00 -3.88%
Volume: 3.60M
June 25, 2021 11:30a
P/E Ratio
80.15
Dividend Yield
1.36%
Market Cap
¥3460.30 billion
Rev. per Employee
¥57.48M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,266.49
+24.65 +0.58%
Volume: 1.87B
June 24, 2021 5:29p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.